(Q53424803)

14 May 2018

title

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. (English)

1 reference

14 May 2018

0 references

1 reference

J Jaime Caro

1

1 reference

14 May 2018

Denis Getsios

series ordinal

2

1 reference

14 May 2018

Ingrid Caro

series ordinal

3

1 reference

14 May 2018

Judith A O'Brien

series ordinal

4

1 reference

14 May 2018

publication date

1 January 2002

1 reference

14 May 2018

published in

PharmacoEconomics

1 reference

14 May 2018

volume

20

1 reference

14 May 2018

issue

9

1 reference

14 May 2018

page(s)

593-602

1 reference

14 May 2018

https://scigraph.springernature.com/pub.10.2165/00019053-200220090-00003

exact match

0 references

cites work

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association

1 reference

12 December 2020

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

12 December 2020

Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis

1 reference

12 December 2020

Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.

1 reference

12 December 2020

Venous thromboembolism

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis

1 reference

12 December 2020

Does this patient have deep vein thrombosis?

1 reference

12 December 2020

Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis

1 reference

12 December 2020

Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications

1 reference

12 December 2020

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

1 reference

12 December 2020

Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden

1 reference

12 December 2020

Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis

1 reference

12 December 2020

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis

1 reference

12 December 2020

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

12 December 2020

Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism

1 reference

12 December 2020

A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study

1 reference

12 December 2020

A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

1 reference

12 December 2020

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

12 December 2020

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

1 reference

12 December 2020

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

1 reference

12 December 2020

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

12 December 2020

Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).

1 reference

12 December 2020

Low molecular weight heparin: a critical analysis of clinical trials

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

12 December 2020

Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program

1 reference

12 December 2020

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective

1 reference

12 December 2020

Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial

1 reference

12 December 2020

Low molecular weight versus unfractionated heparin. A clinical and economic appraisal

1 reference

12 December 2020

Oral anticoagulant drugs

1 reference

12 December 2020

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

12 December 2020

Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin

1 reference

12 December 2020

Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

12 December 2020

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

1 reference

12 December 2020

Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

12 December 2020

10.2165/00019053-200220090-00003

Identifiers

DOI

1 reference

14 May 2018

Dimensions Publication ID

1004997562

0 references

1 reference

14 May 2018